Shares of Abbott Laboratories (NYSE:ABT) fell $-0.15 during today’s regular trading session, a -0.34% decrease from the previous closing price of $43.68. The company’s shares traded on weaker-than-usual volume today: $4.59M shares changed hands while the stock’s average volume is 6.60M shares per day. Abbott Laboratories (ABT) has declined $0.60, or -1.36%, in the last 30 days. This year-to-date, the company’s shares have increased $5.12, or +13.33%. Over the last 12 months, ABT’s stock price has risen $5.55, or +14.61%. The company’s 52-week range is $36.76 to $45.84.
Abbott Laboratories (ABT) Earnings Surprises
Abbott Laboratories announced its recent quarter financial results after the market close on 19/04/2017, crushing consensus estimates with both its revenue and earnings. Abbott Laboratories posted net revenue of 6.34B, beating Wall Street analysts who had forecast $6.15B. The company reported EPS of $0.48, above the consensus estimate calling for EPS of $0.43 – a positive surprise of 11.63%.
Before that, quarter ending December 2016, Abbott Laboratories also surprised analysts by beating the consensus estimate. The Wall Street forecast had projected $0.65 per share, and the company reported EPS of $0.65 – also a 0.67% positive surprise. Revenue during the period amounted to $5.33B, while analysts were anticipating $5.38B.
In the quarter ending September 2016, Abbott Laboratories delivered an even larger earnings beat. Analysts, on average, were expecting $0.58 per share, and the company reported EPS of $0.59 – amounting to a positive surprise of 1.50%. Revenue during that quarter was posted at $5.3B, whereas the consensus estimate was predicting $5.29B.
The company is scheduled to announce its next quarterly financial results on 19/07/2017 after the market close. The average EPS estimate of 9 Wall Street analysts is $0.60 per share, compared to the company’s reported EPS of $0.55 per share in the year-ago quarter. Analysts are forecasting Abbott Laboratories to report revenue of about $6.63B, versus the $5.33B posted last year.
Abbott Laboratories (ABT) Consensus Estimates and Price Target
The company’s consensus rating is currently Strong Buy, with 9 analysts rating it a Strong Buy, and 4 analysts rating it with a Hold. The average 12-month price target, as forecast by analysts, is $48.08, 10.45% higher than the company’s closing price today.